Publication Name	World Journal of Clinical Oncology
Manuscript ID	54865
Country	Egypt

Received	2020-03-12 22:18
Peer-Review Started	2020-03-02 04:22
To Make the First Decision
Return for Revision	2020-04-22 22:02
Revised	2020-04-28 02:23
Second Decision	2020-05-29 06:50
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-05-30 22:05
Articles in Press	2020-05-30 22:05
Publication Fee Transferred
Edit the Manuscript by Language Editor	2020-06-05 16:52
Typeset the Manuscript	2020-07-17 05:57
Publish the Manuscript Online	2020-07-20 02:28

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Biochemistry & Molecular Biology
Manuscript Type	Minireviews
Article Title	Why natural killer cells in triple negative breast cancer?
Manuscript Source	Invited Manuscript
All Author List	Mustafa Abdel-Latif and Rana Ahmed Youness
Funding Agency and Grant Number
Corresponding Author	Rana Ahmed Youness, BSc, PhD, Lecturer, Research Associate, Pharmaceutical Biology Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, El Tagamoa El Khames, Cairo 11835, Egypt. rana.youness21@gmail.com
Key Words	Triple negative breast cancer; Natural killer cells; Immne checkpoint blockades; Programmed death-ligand 1; Cytotoxic T-lymphocyte-associated protein 4; Natural killer lectin-like group 2 member D
Core Tip	Triple-negative breast cancer (TNBC) patients are the least fortunate in terms of prognosis and conventional therapeutic approaches. In this review, we are focusing on the bright side of the story; TNBC patients are recently considered the patients of choice when it comes to immunotherapy. We are shedding the light onto the immune-checkpoint blockades such as programmed death-ligand 1 inhibitors and its recently discovered side-effects and resistance cases that started to appear in the clinics. In such context, we tried to drive the researchers' attention to a very potential weapon known as the innate immune system and its native soldiers which are the natural killer cells.
Publish Date	2020-07-20 02:28
Citation	Abdel-Latif M, Youness RA. Why natural killer cells in triple negative breast cancer? World J Clin Oncol 2020; 11(7): 464-476
URL	https://www.wjgnet.com/2218-4333/full/v11/i7/464.htm
DOI	https://dx.doi.org/10.5306/wjco.v11.i7.464

Full Article (PDF)	WJCO-11-464.pdf
Full Article (Word)	WJCO-11-464.docx
Manuscript File	54865-Review-Filipodia .docx
Answering Reviewers	54865-Answering reviewers.pdf
Audio Core Tip	54865-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	54865-Conflict-of-interest statement.pdf
Copyright License Agreement	54865-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	54865-Language certificate.pdf
Peer-review Report	54865-Peer-review(s).pdf
Scientific Misconduct Check	54865-Scientific misconduct check.pdf
Scientific Editor Work List	54865-Scientific editor work list.pdf